NasdaqGS:BRKRLife Sciences
Is Bruker (BRKR) Quietly Recasting Its Diagnostic Edge With New Automated, AI-Driven Platforms?
Earlier in April 2026, Bruker expanded its portfolio with the European launch of the MyGenius PRO molecular diagnostics platform, broad enhancements to its MALDI and IR Biotyper microbiology solutions, and new NMR and DNP products targeting higher sensitivity and automation across research and applied workflows.
Together, these launches highlight how Bruker is concentrating on higher-throughput, automated, and AI-enabled systems that deepen its presence in infectious disease testing and...